![](https://monteverdelaw.com/wp-content/uploads/case-logo/genmark-diagnostics-inc.png)
GenMark Diagnostics, Inc. (GNMK) relating to its proposed acquisition by Roche Holdings, Inc. Under the terms of the agreement, GNMK shareholders will receive $24.05 per share in cash.
GenMark Diagnostics, Inc. (GNMK) relating to its proposed acquisition by Roche Holdings, Inc. Under the terms of the agreement, GNMK shareholders will receive $24.05 per share in cash.